AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6402914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 60 mg/day orally)
Number of subjects: 30
Study 6402914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30275356 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 20
Study 30275356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLCB)
Number of subjects: 20
Study 25820921 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based exposure with response prevention
Number of subjects: 127
Study 24898680 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and early postoperative rehabilitation (starting two weeks after surgery)
Number of subjects: 380
Study 24898680 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and late postoperative rehabilitation (starting six weeks after surgery)
Number of subjects: 380
Study 24898680 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative rehabilitation alone
Number of subjects: 380
Study 24898680 — intervention group
Group type: COMPARATOR
Intervention: Today's standard care (postoperative rehabilitation initiated six weeks after surgery)
Number of subjects: 380
Study 23116022 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulator Lavomax and basic treatment: azithromycin (1.0 g once a week for 3 weeks), Celebrex, physiotherapy (low‐intensity laser radiation), prostate massage
Number of subjects: 114
Study 23116022 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 114
Study 19536571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 25% protrusion position
Number of subjects: 17
Study 19536571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 50% protrusion position
Number of subjects: 17
Study 19536571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 75% protrusion position
Number of subjects: 17
Study 18609142 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir (VX-950)
Number of subjects: 54
Study 18609142 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN plus telaprevir
Number of subjects: 54
Study 18609142 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN plus placebo
Number of subjects: 54
Study 16022758 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (HGI) trial
Number of subjects: 9
Study 16022758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) trial
Number of subjects: 9
Study 14619336 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid resistant (SR) patients
Number of subjects: 23
Study 14619336 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid sensitive (SS) patients
Number of subjects: 23
Study 14619336 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study 14619336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial wall thickness
Number of subjects: 23
Study 14619336 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between SR and SS patients
Number of subjects: 23
Study 11094034 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA plus BT (57 patients)
Number of subjects: 113
Study 11094034 — intervention group
Group type: COMPARATOR
Intervention: PTA (56 patients)
Number of subjects: 113
Study 8683967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 g/kg alcohol dose
Number of subjects: 10
Study 8683967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g/kg alcohol dose
Number of subjects: 10
Study 8683967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g/kg alcohol dose
Number of subjects: 10
Study 8683967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2003373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture twice a week for two months
Number of subjects: 17
Study 6342554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 79
Study 6342554 — intervention group
Group type: COMPARATOR
Intervention: 2.5% albumin‐lactated Ringer's solution
Number of subjects: 79
Study 6342554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 79
Study 6342554 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid group
Number of subjects: 79
Study 31867833 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one speech and language therapist (SLT) intervention
Number of subjects: 49
Study 31867833 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 49
Study 31867833 — intervention group
Group type: COMPARATOR
Intervention: One-to-one SLT intervention
Number of subjects: 49
Study 31867833 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiom explanation skills
Number of subjects: 49
Study 31867833 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiom use skills
Number of subjects: 49
Study 31867833 — intervention group
Group type: COMPARATOR
Intervention: Control items
Number of subjects: 49
Study 30852854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy-enhancing therapy (IET)
Number of subjects: 237
Study 30852854 — intervention group
Group type: EXPERIMENTAL
Intervention: General health and wellness intervention (GHW)
Number of subjects: 237
Study 30852854 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 237
Study 29600580 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (0.4 mg/kg per day) plus nanocurcumin (3 g/day)
Number of subjects: 0
Study 29600580 — intervention group
Group type: COMPARATOR
Intervention: Acitretin
Number of subjects: 0
Study 27864247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-delivered structured intervention at discharge and tailored follow-up postdischarge
Number of subjects: 0
Study 27864247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist delivered usual care at discharge
Number of subjects: 0
Study 27864247 — intervention group
Group type: COMPARATOR
Intervention: Control arm (patients discharged during weekends or after hours)
Number of subjects: 0
Study 25143372 — intervention group
Group type: EXPERIMENTAL
Intervention: A&T social franchise model (A&T-I; mass media + social franchise)
Number of subjects: 2045
Study 25143372 — intervention group
Group type: COMPARATOR
Intervention: A&T nonintensive areas (A&T-NI; mass media only)
Number of subjects: 2045
Study 21913224 — intervention group
Group type: COMPARATOR
Intervention: Safinamide 200 mg
Number of subjects: 269
Study 21913224 — intervention group
Group type: COMPARATOR
Intervention: Safinamide 100 mg
Number of subjects: 269
Study 21913224 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 269
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐minute sodium hypochlorite (NaOCl)
Number of subjects: 50
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐hour sodium hypochlorite (NaOCl)
Number of subjects: 50
Study 17559536 — intervention group
Group type: COMPARATOR
Intervention: No disinfectant
Number of subjects: 50
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfected PE impressions
Number of subjects: 50
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-disinfected and disinfected VPS and PE impressions
Number of subjects: 50
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: All disinfectants (NaOCl and dual phenol)
Number of subjects: 50
Study 17559536 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing exposure to NaOCl
Number of subjects: 50
Study 10861157 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular midazolam
Number of subjects: 55
Study 10861157 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 55
Study 9202789 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 159
Study 9202789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 1532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (AA)
Number of subjects: 20
Study 1532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (AP)
Number of subjects: 20
Study 1532321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP)
Number of subjects: 20
Study 3572102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as an immuno-stimulator for 1 year along with chemotherapy
Number of subjects: 20
Study 3572102 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 20
Study 30502984 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tranexamic acid (TXA)
Number of subjects: 34
Study 30502984 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 34
Study 25539571 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 2854
Study 25539571 — intervention group
Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 2854
Study 22520084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol 6.25 mcg once-daily
Number of subjects: 75
Study 22520084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol 12.5 mcg once-daily
Number of subjects: 75
Study 22520084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg once-daily
Number of subjects: 75
Study 22520084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol 6.25 mcg twice-daily
Number of subjects: 75
Study 22520084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 20500310 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care self-efficacy enhancement programme (SCSEEP)
Number of subjects: 101
Study 20500310 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 101
Study 18347203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 64
Study 18347203 — intervention group
Group type: COMPARATOR
Intervention: Respiratory rehabilitation (RR)
Number of subjects: 64
Study 16179089 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (n = 245)
Number of subjects: 490
Study 16179089 — intervention group
Group type: COMPARATOR
Intervention: artesunate and mefloquine (n = 245)
Number of subjects: 490
Study 12087881 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted normobaric hypoxia (INH)
Number of subjects: 63
Study 12087881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10622344 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 32
Study 10622344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9138981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induced labor (PI)
Number of subjects: 82
Study 9138981 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean section (CCC)
Number of subjects: 82
Study 9138981 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean section (CCE)
Number of subjects: 82
Study 1916007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day alpha‐glycerylphosphorylcholine (alpha‐GPC)
Number of subjects: 120
Study 1916007 — intervention group
Group type: COMPARATOR
Intervention: 1 g/day cytosine diphosphocholine (CDP)
Number of subjects: 120
Study 30291532 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious intervention (12 sessions of 30-45 minutes each)
Number of subjects: 88
Study 30291532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 30969960 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel from Nanjing Pharmaceutical Factory (NPF), China
Number of subjects: 152
Study 30969960 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel from Merck Limited Partnership (KgaA), Germany
Number of subjects: 152
Study 27662605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary NiTi files
Number of subjects: 130
Study 27662605 — intervention group
Group type: COMPARATOR
Intervention: SAF (self-adjusting file) system
Number of subjects: 130
Study 27662605 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF group (teeth with vital pulps)
Number of subjects: 130
Study 27662605 — intervention group
Group type: EXPERIMENTAL
Intervention: SAF group (teeth with nonvital pulps)
Number of subjects: 130
Study 27662605 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with pulpal necrosis
Number of subjects: 130
Study 26110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-adrenergic antagonist)
Number of subjects: 0
Study 26110636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26110636 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress protocol
Number of subjects: 0
Study 26110636 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study 23831177 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual combined with animal-assisted therapy (AAT) administered over 10 weekly sessions
Number of subjects: 65
Study 23831177 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 65
Study 21594587 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (12-week web-based support group)
Number of subjects: 27
Study 21594587 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study 20024643 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP concentration > 50 pg/ml
Number of subjects: 802
Study 20024643 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP concentration median 11.3 pg/ml
Number of subjects: 802
Study 17663620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy for 2 months
Number of subjects: 26
Study 17663620 — intervention group
Group type: COMPARATOR
Intervention: Information session (control)
Number of subjects: 26
Study 16285355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study 16285355 — intervention group
Group type: COMPARATOR
Intervention: Combination antimicrobial therapy
Number of subjects: 0
Study 12140300 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidneys from donors without a heartbeat
Number of subjects: 244
Study 12140300 — intervention group
Group type: COMPARATOR
Intervention: Kidneys from donors with a heartbeat
Number of subjects: 244
Study 10189538 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.07/10-g monofilament at five sites on the right foot
Number of subjects: 332
Study 10189538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sites 3 and 4 for monofilament testing
Number of subjects: 332
Study 10189538 — intervention group
Group type: EXPERIMENTAL
Intervention: Different methodologies for testing
Number of subjects: 332
Study 10189538 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament with buckling force of 5 g and 15 g
Number of subjects: 332
Study 7754764 — intervention group
Group type: EXPERIMENTAL
Intervention: alkylated immunoglobulin G intravenous preparation (IGIV) 200 mg/kg daily x 3 days + aspirin
Number of subjects: 6
Study 7754764 — intervention group
Group type: EXPERIMENTAL
Intervention: alkylated immunoglobulin G intravenous preparation (IGIV) 400 mg/kg daily x 3 days + aspirin
Number of subjects: 6
Study 7754764 — intervention group
Group type: EXPERIMENTAL
Intervention: native IGIV 200 mg/kg daily x 5 days + aspirin
Number of subjects: 6
Study 7754764 — intervention group
Group type: EXPERIMENTAL
Intervention: native IGIV 400 mg/kg daily x 5 days + aspirin
Number of subjects: 6
Study 2148508 — intervention group
Group type: EXPERIMENTAL
Intervention: Longevity-Antihypertensive-Mixture (LAM)
Number of subjects: 65
Study 2148508 — intervention group
Group type: COMPARATOR
Intervention: Apocyhum Venetum L. Fluid (AVLF)
Number of subjects: 65
Study 6945046 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg PGE2 for primigravidas
Number of subjects: 0
Study 6945046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg PGE2 for multigravidas
Number of subjects: 0
Study 6945046 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 0
Study 6945046 — intervention group
Group type: COMPARATOR
Intervention: Conventional induction by amniotomy and immediate oxytocin titration
Number of subjects: 0
Study 6945046 — intervention group
Group type: COMPARATOR
Intervention: Conventional induction
Number of subjects: 0
Study 30502372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly until complete resolution of SRF and IRF (intensive arm: SRF intolerant)
Number of subjects: 349
Study 30502372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with treatment aimed at resolution of all IRF only (relaxed arm: SRF tolerant)
Number of subjects: 349
Study 28530238 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (AD treatment)
Number of subjects: 0
Study 28530238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 25567329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 52
Study 25567329 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga added to aerobic exercise
Number of subjects: 52
Study 23684156 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch saphenous vein
Number of subjects: 108
Study 23684156 — intervention group
Group type: COMPARATOR
Intervention: Radial artery graft
Number of subjects: 108
Study 23684156 — intervention group
Group type: COMPARATOR
Intervention: Left internal thoracic artery graft
Number of subjects: 108
Study 20568012 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-tutoring activities
Number of subjects: 58
Study 20568012 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game
Number of subjects: 58
Study 20568012 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-tutoring activities + Good Behavior Game
Number of subjects: 58
Study 20568012 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study 19910826 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 12
Study 16951011 — intervention group
Group type: EXPERIMENTAL
Intervention: Content and Notification
Number of subjects: 887
Study 16951011 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification Only
Number of subjects: 887
Study 16951011 — intervention group
Group type: EXPERIMENTAL
Intervention: Content Only
Number of subjects: 887
Study 16951011 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification and Content
Number of subjects: 887
Study 16951011 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 887
Study 15587599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariston Liner and Ariston pHc (Vivadent, Schaan, FL)
Number of subjects: 0
Study 11518443 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI) assessment
Number of subjects: 104
Study 11518443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar infarcts
Number of subjects: 104
Study 11518443 — intervention group
Group type: COMPARATOR
Intervention: Total anterior circulation infarcts
Number of subjects: 104
Study 9466127 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d.
Number of subjects: 15
Study 9466127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 9466127 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d. (in patients with > or = 20% reduction in triglyceride levels)
Number of subjects: 15
Study 8536013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 ml intra-articular injection)
Number of subjects: 60
Study 8536013 — intervention group
Group type: COMPARATOR
Intervention: Saline with contrast dye (5 ml intra-articular injection)
Number of subjects: 60
Study 3312048 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS)
Number of subjects: 60
Study 3312048 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (IM)
Number of subjects: 60
Study 29879676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 996
Study 29879676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study 27113249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 284
Study 27113249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 27113249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 284
Study 24428972 — intervention group
Group type: EXPERIMENTAL
Intervention: LTB4 added to activated CD8(+) T cells
Number of subjects: 0
Study 24428972 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0
Study 24428972 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment in SS asthma
Number of subjects: 0
Study 24428972 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment in SR asthma
Number of subjects: 0
Study 24428972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured CD8(+) T cells
Number of subjects: 0
Study 24428972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured CD4(+) T cells from controls and patients with SS asthma
Number of subjects: 0
Study 24428972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SR asthma
Number of subjects: 0
Study 22424016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 190
Study 22424016 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 190
Study 19939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XR 150 mg
Number of subjects: 591
Study 19939870 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg
Number of subjects: 591
Study 19939870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 19055806 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic tailored intervention (three tailored letters over four months targeting psychosocial determinants of physical activity)
Number of subjects: 0
Study 19055806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus (same as basic tailored intervention plus tailored information about physical activity opportunities in the specific environment, access to a forum and e-buddy system)
Number of subjects: 0